Granted Patent
B2
US 12,311,028 · App. 18/140,289 · Granted May 27, 2025
Polymer-based macromolecular prodrugs
Inventors:
Michael Chorny (Huntingdon Valley, PA); Ivan Alferiev (Clementon, NJ); Garrett M. Brodeur (Wynnewood, PA)
Assignee:
The Children's Hospital of Philadelphia
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided are macromolecular prodrugs in which camptothecin analogs are covalently bonded to polymers via ester bonds that are labile under physiological conditions. Also provided are methods of treating cancer, especially neuroblastoma with the macromolecular prodrugs.
Claims (16)
1. A method of treating a subject with a solid tumor, comprising administering intravenously to the subject in need thereof an effective amount of the macromolecular prodrug which is PEG-[SN22] 4 , having the following structure:
wherein:
n=110 in average and
PE is
2. The method of claim 1 , wherein the subject is human.
3. A method of treating a subject with cancer, comprising administering intravenously to the subject in need thereof an effective amount of the macromolecular prodrug which is PEG-[SN22] 4 , having the following structure:
wherein:
n=110 in average and
PE is
4. The method of claim 3 , wherein the subject is human.
5. The method of claim 3 , wherein the cancer is neuroblastoma.
6. A method of treating a subject with a brain tumor, comprising administering intravenously to the subject in need thereof an effective amount of the macromolecular prodrug which is PEG-[SN22] 4 , having the following structure:
wherein:
n=110 in average and
PE is
7. The method of claim 6 , wherein the subject is human.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 19, 2023
From: CHORNY, MICHAEL; ALFERIEV, IVAN; BRODEUR, GARRETT
To: THE CHILDREN'S HOSPITAL OF PHILADELPHIA
Reel/Frame 064954/0824 →
Continuity (4)
Division
16969790
Provisional Application
62732199
· Sep 17, 2018
References Cited (107)
US 7744861B2
· Zhao et al.
· 2010
[cited by applicant]
US 8263062B2
· Zhao et al.
· 2012
[cited by applicant]
US 8318145B2
· Zhao et al.
· 2012
[cited by applicant]
US 8394365B2
· Zhao et al.
· 2013
[cited by applicant]
US 8617558B2
· Govindan et al.
· 2013
[cited by applicant]
US 8771662B2
· Zhao et al.
· 2014
[cited by applicant]
US 8906353B2
· Eldon et al.
· 2014
[cited by applicant]
US 9226969B2
· Chong et al.
· 2016
[cited by applicant]
US 9320808B2
· Chong et al.
· 2016
[cited by applicant]
US 9333200B2
· Zhao et al.
· 2016
[cited by applicant]
US 9801873B2
· Eldon et al.
· 2017
[cited by applicant]
US 9808533B2
· Zhao et al.
· 2017
[cited by applicant]
US 9863949B2
· Hoch et al.
· 2018
[cited by applicant]
US 20040258754A1
· Alakhov et al.
· 2004
[cited by applicant]
US 20070254019A1
· Zamboni et al.
· 2007
[cited by applicant]
US 20080194612A1
· Zhao et al.
· 2008
[cited by applicant]
US 20090074074A1
· Au et al.
· 2009
[cited by applicant]
US 20100098654A1
· Pastorino et al.
· 2010
[cited by applicant]
US 20120171201A1
· Sapra
· 2012
[cited by applicant]
US 20130143909A1
· Chong et al.
· 2013
[cited by applicant]
US 20140371258A1
· Gu et al.
· 2014
[cited by applicant]
US 20160200867A1
· Kozłowski et al.
· 2016
[cited by applicant]
US 20170246171A1
· Strum et al.
· 2017
[cited by applicant]
US 20180095085A1
· Hoch et al.
· 2018
[cited by applicant]
US 20190049450A1
· Chia et al.
· 2019
[cited by applicant]
US 20190375732A1
· Hung et al.
· 2019
[cited by applicant]
US 20200016149A1
· Zhao et al.
· 2020
[cited by applicant]
US 20200163956A1
· Abrams et al.
· 2020
[cited by applicant]
CN 101385860A
· 2009
[cited by applicant]
CN 102215688A
· 2011
[cited by applicant]
CN 102626518A
· 2012
[cited by applicant]
EP 2626083A1
· 2013
[cited by applicant]
JP 2002255821A
· 2002
[cited by applicant]
JP 2012503602A
· 2012
[cited by applicant]
JP 2012506380A
· 2012
[cited by applicant]
JP 2016531895A
· 2016
[cited by applicant]
WO 9952861A1
· 1999
[cited by applicant]
WO 2005028539A2
· 2005
[cited by applicant]
WO 2010036335A1
· 2010
[cited by applicant]
WO 2010048018A1
· 2010
[cited by applicant]
WO 2019090141A1
· 2019
[cited by applicant]
WO 2020169004A1
· 2020
[cited by applicant]
Japanese Notice of Reasons for Rejection for Japanese Application No. 2021-514531, mailed Aug. 29, 2023 with translation, 9 pages.
[cited by applicant]
Chinese Office Action for Chinese Application No. 201980060783.3, dated Dec. 7, 2023 with English translation, 21 pages.
[cited by applicant]
Raffel, David M, et al., “Radiolabeled Phenethylguanidines: Novel Imaging for Cardiac Sympathetic Neurons and Adrenergic Tumors,” Journal of Medicinal Chemistry, May 3, 2007, vol. 50(9), pp. 1-30.
[cited by applicant]
Office Action issued Apr. 26, 2024, by the China National Intellectual Property Administration, P. R. China in Corresponding Chinese Patent Application No. 201980060783.3 with an English translation of the Office Action…
[cited by applicant]
Ekladious et al., “Polymer—Drug Conjugate Therapeutics: Advances, Insights and Prospects”, Nature Review, vol. 18, Apr. 2019, 22 pages.
[cited by applicant]
Fontaine et al., “PLX038: A PEGylated Prodrug of SN-38 Independent of UGT1A1 Activity”, Cancer Chemotherapy and Pharmacology, 2020, vol. 85, pp. 225-229.
[cited by applicant]
Fontaine et al., “PLX038: A PEGylated Prodrug of SN-38 Independent of UGT1A1 Activity”, Cancer Chemotherapy and Pharmacology, Supporting Information, 2020, 4 pages.
[cited by applicant]
Hoch et al., “Nonclinical Pharmacokinetics and Activity of Etirinotecan Pegol (NKTR-102) a Long-Acting Topoisomerase 1 Inhibitor, in Multiple Cancel Models”, Cancer Chemotherapy Pharmacology, 2014, vol. 74, pp. 1125-113…
[cited by applicant]
Santi et al., “Macromolecular Prodrug That Provides The Irinotecan (CPT-11) Active-Metabolite SN-38 with Ultralong Half-Life, Low Cmax, and Low Glucuronide Formation”, Journal of Medicinal Chemistry, 2014, vol. 57, pp. …
[cited by applicant]
Sapra et al., “Novel Delivery of SN 38 Markedly Inhibits Tumor Growth in Xenografts, Including a Camptothecin-11—Refractory Model”, Clinical Cancer Research, 2008, vol. 14, pp. 1888-1896.
[cited by applicant]
International Preliminary Report on Patentability and Written Opinion for International Application No. PCT/US2019/051457, issued Mar. 9, 2021, 8 pages.
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/051457, dated Nov. 19, 2019, 9 pages.
[cited by applicant]
Ulbrich et al., “Targeted Drug Delivery with Polymers and Magnetic Nanoparticles: Covalent and Noncovalent Approaches, Release Control, and Clinical Studies”, Chemical Reviews, vol. 116, Apr. 25, 2016, pp. 5338-5377.
[cited by applicant]
European Communication pursuant to Article 94(3) for European Application No. 19 863 240.8, dated Feb. 15, 2023, 5 pages.
[cited by applicant]
Brodeur, G., “Description of Research Expertise”, Biomedical Graduate Studies, Aug. 26, 2018, XP055695177, 6 pages.
[cited by applicant]
Zhao et al., “Novel Prodrugs of SN38 using Multiarm Poly(ethylene glycol) Linkers”, 2008, pp. 849-859, vol. 19(4), Bioconjugate Chemistry.
[cited by applicant]
Eurasian Office Action for Eurasian Application No. 202190799, dated Oct. 17, 2022 with translation, 4 pages.
[cited by applicant]
Extended European Search Report for European Application No. 19 863 240.8, dated Jun. 15, 2022, 5 pages.
[cited by applicant]
Pastorino et al., “Tumor Regression and Curability of Preclinical Neuroblastoma Models by PEGylated SN38 (EZN-2208), a Novel Topoisomerase I Inhibitor”, Clinical Cancer Research, vol. 16(19), Oct. 1, 2010, pp. 4809-4821…
[cited by applicant]
Mishra et al., “PEGylation in Anti-Cancer Therapy: An Overview”, Asian Journal of Pharmaceutical Sciences, vol. 11 (3), Jun. 1, 2016, pp. 337-348, XP055444010.
[cited by applicant]
Entire patent prosecution history of U.S. Appl. No. 16/969,790, filed Aug. 13, 2020, entitled, “Polymer-Based Macromolecular Prodrugs”
[cited by applicant]
Entire patent prosecution history of U.S. Appl. No. 17/670,218, filed Feb. 11, 2020, entitled, “Polymer-Based Macromolecular Prodrugs”
[cited by applicant]
Japanese Notice of Reasons for Rejection for Japanese Application No. 2021-514531, mailed Jan. 9, 2024 with translation, 5 pages.
[cited by applicant]
Office Action (Notice of Allowance) issued Nov. 8, 2024, by the National Intellectual Property Administration, P. R. China in corresponding Chinese Patent Application No. 201980060783.3 and an English translation. (7 pa…
[cited by applicant]
New Zealand Examination Report issued Jul. 25, 2024, by the New Zealand Intellectual Property Office in corresponding New Zealand Patent Application No. 773863. (5 pages).
[cited by applicant]
Office Action (Request for the Submission of an Opinion) issued Mar. 21, 2025, by the Intellectual Property Office in corresponding Korean Application No. 10-2021-7011264 and an English translation. (17 pages).
[cited by applicant]